Michael Sperling, AAN 2021: Post-hoc Analysis of Cenobamate for Uncontrolled Focal Seizures
We were delighted to speak with Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss the recent post-hoc analysis of cenobamate for uncontrolled focal seizures, and its intended place in the treatment landscape for epilepsy.
The abstract entitled: ‘Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What did the findings of the recent global, open-label phase 3 study teach us about the efficacy and safety of cenobamate? (0:15)
- What is the rationale for the dose escalating strategy with cenobamate? (5:45)
- What was the rationale for the post-hoc analysis? (6:47)
- What were the findings of this analysis? (7:41)
- What questions remain unanswered? (8:45)
Disclosures: Michael Sperling has received compensation for speaking at CME programs from Neurology Live, Medscape, Projects for Knowledge, International Medical Press, Eisai, and UCB Pharma; and is an advisor for scientific publications for Neurelis; consults for Medtronic with payments to Thomas Jefferson University; and has received research support from Eisai; Medtronic; Neurelis; SK Life Science; Takeda; Xenon; Cerevel; UCB Pharma; and Engage Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Epilepsy
Jacqueline French, AAN 2023: XEN1101, a novel potassium channel modulator for the treatment of focal epilepsy
In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses the needs of adults with focal epilepsy and the mechanisms of action of XEN1101, a novel, potent, selective Kv7.2/7.3 potassium channel. The abstract entitled “XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, […]
Jacqueline French, AAN 2023: X-TOLE phase 2b open-label extension trial of XEN1101 in focal epilepsy – interim data
The randomized, double-blind, placebo-controlled phase IIb study X-TOLE (NCT03796962) is investigating the efficacy of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy. In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses this clinical trial and the outcomes of its open-label extension. The […]
Galia Wilson, Dravet Syndrome UK: DSUK Objectives, directions and support for families and people living with Dravet syndrome
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came together looking for support, resources and information relating to the neurological condition. In this interview, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!